The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Cerebrospinal fluid protein biomarkers for Alzheimer’s disease
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Observations on the brains of demented old people
Tomlinson, B. E., Blessed, G., & Roth, M. (1970) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(70)90063-8 · Cited by 2,084
Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Buée, L., Bussière, T., Buée-Scherrer, V., Delacourte, A., & Hof, P. R. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00019-9 · Cited by 2,015
Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774
Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Cited by
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Self-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Self-citationBiomarkers for Alzheimer's disease: academic, industry and regulatory perspectives
Hampel, H., Frank, R., Broich, K., Teipel, S. J., Katz, R. G., Hardy, J., Herholz, K., Bokde, A. L. W., Jessen, F., Hoessler, Y. C., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3115 · Cited by 631
Self-citationSuppression of glymphatic fluid transport in a mouse model of Alzheimer's disease
Peng, W., Achariyar, T. M., Li, B., Liao, Y., Mestre, H., Hitomi, E., Regan, S., Kasper, T., Peng, S., Ding, F., et al. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.05.015 · Cited by 580
Protein Aggregation in the Brain: The Molecular Basis for Alzheimer’s and Parkinson’s Diseases
Irvine, G. B., El-Agnaf, O. M., Shankar, G. M., & Walsh, D. M. (2008) · Molecular Medicine · doi:10.2119/2007-00100.irvine · Cited by 550
Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease
Blennow, K., Dubois, B., Fagan, A. M., Lewczuk, P., de Leon, M. J., & Hampel, H. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.02.004 · Cited by 455
Self-citationBrain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
M. de la Monte, S. (2012) · Current Alzheimer Research · doi:10.2174/156720512799015037 · Cited by 448
Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift
Golde, T. E., Schneider, L. S., & Koo, E. H. (2011) · Neuron · doi:10.1016/j.neuron.2011.01.002 · Cited by 382
Neurochemical Aftermath of Amateur Boxing
Zetterberg, H., Hietala, M. A., Jonsson, M., Andreasen, N., Styrud, E., Karlsson, I., Edman, Å., Popa, C., Rasulzada, A., Wahlund, L.-O., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.9.1277 · Cited by 356
Self-citationUrate as a Predictor of the Rate of Clinical Decline in Parkinson Disease
Ascherio, A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.247 · Cited by 354
CSF tau/Aβ 42 ratio for increased risk of mild cognitive impairment: A follow-up study
Li, G., Sokal, I., Quinn, J. F., Leverenz, J. B., Brodey, M., Schellenberg, G. D., Kaye, J. A., Raskind, M. A., Zhang, J., Peskind, E. R., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000267428.62582.aa · Cited by 279
Tatebe, H., Kasai, T., Ohmichi, T., Kishi, Y., Kakeya, T., Waragai, M., Kondo, M., Allsop, D., & Tokuda, T. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0206-8 · Cited by 256
Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease
Zetterberg, H., Andreasson, U., Hansson, O., Wu, G., Sankaranarayanan, S., Andersson, M. E., Buchhave, P., Londos, E., Umek, R. M., Minthon, L., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1102 · Cited by 224
Biomarkers for the Early Detection and Progression of Alzheimer's Disease
Counts, S. E., Ikonomovic, M. D., Mercado, N., Vega, I. E., & Mufson, E. J. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0481-z · Cited by 224
Tau in neurodegenerative disease
Gao, Y.-L., Wang, N., Sun, F.-R., Cao, X.-P., Zhang, W., & Yu, J.-T. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.23 · Cited by 222
CSF biomarkers in frontotemporal lobar degeneration with known pathology
Bian, H., Van Swieten, J. C., Leight, S., Massimo, L., Wood, E., Forman, M., Moore, P., de Koning, I., Clark, C. M., Rosso, S., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000311445.21321.fc · Cited by 216
Fluid Biomarkers in Alzheimer Disease
Blennow, K., Zetterberg, H., & Fagan, A. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006221 · Cited by 208
Self-citationVarga, A. W., Wohlleber, M. E., Giménez, S., Romero, S., Alonso, J. F., Ducca, E. L., Kam, K., Lewis, C., Tanzi, E. B., Tweardy, S., et al. (2016) · SLEEP · doi:10.5665/sleep.6240 · Cited by 203
Self-citationLongitudinal stability of CSF biomarkers in Alzheimer's disease
Blennow, K., Zetterberg, H., Minthon, L., Lannfelt, L., Strid, S., Annas, P., Basun, H., & Andreasen, N. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.03.064 · Cited by 193
Self-citationBjerke, M., Zetterberg, H., Edman, Å., Blennow, K., Wallin, A., & Andreasson, U. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110566 · Cited by 180
“ral (FTD), and Lewy body dementias [5].”
Self-citationSunderland, T., Mirza, N., Putnam, K. T., Linker, G., Bhupali, D., Durham, R., Soares, H., Kimmel, L., Friedman, D., Bergeson, J., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.07.021 · Cited by 179
Quantitative EEG power and synchronization correlate with Alzheimer's disease CSF biomarkers
Smailovic, U., Koenig, T., Kåreholt, I., Andersson, T., Kramberger, M. G., Winblad, B., & Jelic, V. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.11.005 · Cited by 177
McKeever, P. M., Schneider, R., Taghdiri, F., Weichert, A., Multani, N., Brown, R. A., Boxer, A. L., Karydas, A., Miller, B., Robertson, J., et al. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1032-x · Cited by 166
Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease
Welge, V., Fiege, O., Lewczuk, P., Mollenhauer, B., Esselmann, H., Klafki, H.-W., Wolf, S., Trenkwalder, C., Otto, M., Kornhuber, J., et al. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-008-0177-6 · Cited by 152
Circulating Biomarkers of Cognitive Decline and Dementia
Solfrizzi, V., D'Introno, A., Colacicco, A. M., Capurso, C., Todarello, O., Pellicani, V., Capurso, S. A., Pietrarossa, G., Santamato, V., Capurso, A., et al. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.06.015 · Cited by 120
Disease modifying therapy for AD?1
Golde, T. E. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04211.x · Cited by 117
The keystone of Alzheimer pathogenesis might be sought in Aβ physiology
Puzzo, D., Gulisano, W., Arancio, O., & Palmeri, A. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.08.039 · Cited by 116
Hormetic effect of amyloid-beta peptide in synaptic plasticity and memory.
Puzzo, D., Privitera, L., & Palmeri, A. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.12.020 · Cited by 95
Biomarkers in Neurodegenerative Diseases
Jeromin, A., & Bowser, R. (2017) · Advances in Neurobiology · doi:10.1007/978-3-319-57193-5_20 · Cited by 92
Targeting Aβ and tau in Alzheimer's disease, an early interim report
Golde, T. E., Petrucelli, L., & Lewis, J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.035 · Cited by 89
“The second reason is that we have the ability to monitor multiple biomarkers that provide a number of important readouts (Blennow, 2004).”
Soliman, H. M., Ghonaim, G. A., Gharib, S. M., Chopra, H., Farag, A. K., Hassanin, M. H., Nagah, A., Emad-Eldin, M., Hashem, N. E., Yahya, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910794 · Cited by 81
Feng, M.-G., Liu, C.-F., Chen, L., Feng, W.-B., Liu, M., Hai, H., & Lu, J.-M. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.043 · Cited by 80
Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease
Skogseth, R., Mulugeta, E., Ballard, C., Rongve, A., Nore, S., Alves, G., & Aarsland, D. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000137671 · Cited by 71
Preclinical AD Workgroup staging: Pathological correlates and potential challenges
Jicha, G. A., Abner, E. L., Schmitt, F. A., Kryscio, R. J., Riley, K. P., Cooper, G. E., Stiles, N., Mendiondo, M. S., Smith, C. D., Van Eldik, L. J., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.02.018 · Cited by 71
The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease
Blennow, K., & Zetterberg, H. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.12.012 · Cited by 69
Self-citationBiomarkers in translational research of Alzheimer’s Disease
Tarawneh, R., & Holtzman, D. M. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.04.006 · Cited by 67
Haldenwanger, A., Eling, P., Kastrup, A., & Hildebrandt, H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101203 · Cited by 54
Ramcharitar, J., Albrecht, S., Afonso, V. M., Kaushal, V., Bennett, D. A., & LeBlanc, A. C. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182a0a39f · Cited by 47
Urine Neural Thread Protein Measurements in Alzheimer Disease
Youn, Y. C., Park, K.-W., Han, S.-H., & Kim, S. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2010.03.004 · Cited by 45
“The inclusion criteria for AD patients were (1) an age of 50 or older; (2) probable AD was diagnosed using the National Institute of Neurological Communicative Disorders and Stroke and using the Alzheimer Disease and Related Disorders Association (NINCDS-ADRDA) criteria; (3) magnetic resonance imaging (MRI) studies sh…”
BackgroundMethodInfluentialUnveiling the Complex Role of Exosomes in Alzheimer’s Disease
Sun, M., & Chen, Z. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s466821 · Cited by 39
“145,146 Even in the early to mid-stages of AD, these biomarkers could provide diagnostically useful information.”
BackgroundProgress in the development of new drugs in Alzheimer's disease
Piau, A., Nourhashémi, F., Hein, C., Caillaud, C., & Vellas, B. (2011) · The Journal of nutrition, health and aging · doi:10.1007/s12603-011-0012-x · Cited by 32
Alzheimer's disease biomarkers: correspondence between human studies and animal models
Sabbagh, J. J., Kinney, J. W., & Cummings, J. L. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.04.010 · Cited by 27
Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease—From Brain Starch to Bench and Bedside
Pawlowski, M., Meuth, S., & Duning, T. (2017) · Diagnostics · doi:10.3390/diagnostics7030042 · Cited by 25
A missense variant in SHARPIN mediates Alzheimer’s disease-specific brain damages
Park, J. Y., Lee, D., Lee, J. J., Gim, J., Gunasekaran, T. I., Choi, K. Y., Kang, S., Do, A. R., Jo, J., Park, J., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01680-5 · Cited by 21
Metadata
- Authors
- Blennow, K.
- Venue
- NeuroRX
- Published
- 2004-04
- Volume
- 1
- Issue
- 2
- Pages
- 213-225
- ISSN
- 1545-5343 (ISSN-L)
- OpenAlex
- W2057236704
- Cited by
- 477
- References
- 150
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.